Propofol inhibits the resistance of ovarian cancer cells to cisplatin by regulating the miR-374a/FOXO1 signaling pathway, which provides more favorable evidence for propofol in the anesthesia of ovarian cancer patients (Sun et al., 2020). Here, FOXO1 is linked to ovarian carcinoma.